炎症性肠病（IBD）包括溃疡性结肠炎和克罗恩病，是一种以胃肠道复发性和缓解性炎症为特征的慢性疾病。发病机制涉及遗传、环境和免疫因素的复杂相互作用。在过去的几十年里，随着生物制剂，特别是抗 TNF（肿瘤坏死因子）药物的引入，治疗范式发生了显着的变化，标志着显着的进步。抗 TNF 疗法，包括英夫利昔单抗、阿达木单抗、戈利木单抗和聚乙二醇赛妥珠单抗，可有效诱导和维持缓解、促进粘膜愈合并改善中重度 IBD 患者的生活质量。早期和适当使用这些药物可以减轻疾病进展并减少对皮质类固醇的依赖，从而改善患者的长期预后。然而，这些疗法价格昂贵，并且与潜在的副作用相关，包括增加感染和恶性肿瘤的风险。这篇综述讨论了抗 TNF 药物在 IBD 管理中的机制、临床疗效、安全性和治疗定位，并整合了当前的韩国治疗指南。

Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, is a chronic condition characterized by relapsing and remitting inflammation of the gastrointestinal tract. The pathogenesis involves a complex interplay of genetic, environmental, and immune factors. Treatment paradigms have evolved significantly over the past few decades, with the introduction of biologics, particularly anti-TNF (tumor necrosis factor) agents, marking a significant advancement. Anti-TNF therapies, including infliximab, adalimumab, golimumab, and certolizumab pegol, have efficacy in inducing and maintaining remission, promoting mucosal healing, and improving the quality of life in moderate to severe IBD patients. The early and appropriate use of these agents can mitigate disease progression and reduce the dependency on corticosteroids, enhancing long-term patient outcomes. Nevertheless, these therapies are expensive and are associated with potential adverse effects, including increased risk of infections and malignancies. This review discusses the mechanisms, clinical efficacy, safety profiles, and therapeutic positioning of anti-TNF agents in IBD management, integrating current Korean treatment guidelines.